Antitumor Activity of Ruditapes philippinarum Polysaccharides Through Mitochondrial Apoptosis in Cellular and Zebrafish Models

Mengyue Liu, Weixia Wang, Haoran Wang, Shuang Zhao, Dongli Yin, Haijun Zhang, Changqing Zou, Shengcan Zou, Jia Yu, Yuxi WeiMarine 2025 · DOI

TL;DR

This study investigates the anti-colorectal cancer (CRC) potential of a novel polysaccharide, ERPP, extracted from the clam Ruditapes philippinarum. ERPP demonstrates significant anti-tumor activity both in cell cultures and in a zebrafish model by inducing mitochondrial apoptosis, inhibiting angiogenesis, and exhibiting antioxidant properties, suggesting its promise as a functional food or therapeutic agent for CRC.

What Problem Does This Paper Address?

Colorectal cancer (CRC) remains a major global health concern, driving the urgent need for new and effective therapeutic strategies. While conventional treatments like surgery, chemotherapy, and radiotherapy exist, they often come with severe side effects and limitations, such as drug resistance and patient heterogeneity. Immunotherapy offers a promising avenue, but its efficacy can be hampered by variations in patient immune profiles. This has spurred research into natural compounds, particularly polysaccharides, which are known for their diverse biological activities and potential anti-cancer properties. However, the specific mechanisms and in vivo efficacy of many marine-derived polysaccharides, like those from Ruditapes philippinarum, remain underexplored. This paper aims to fill this gap by comprehensively evaluating the anti-CRC activity of an enzymatically extracted polysaccharide (ERPP) from Ruditapes philippinarum, focusing on its mechanisms of action in both cellular and animal models.

Methods

The researchers employed a multi-pronged approach to assess ERPP's anti-cancer effects:

  • In Vitro Assays:
    • Cell Viability (CCK-8): To determine the direct impact of ERPP on the proliferation of various cancer cell lines, including HT-29.
  • Clonogenic Survival (Colony Formation Assay): To evaluate ERPP's ability to inhibit the long-term proliferative potential of single cancer cells.
  • Cell Migration (Scratch Wound Healing Assay): To assess ERPP's effect on the migratory capacity of cancer cells, a key factor in metastasis.
  • Apoptosis Detection (Annexin V-FITC/PI Staining): To quantify the induction of programmed cell death in cancer cells treated with ERPP using flow cytometry.
  • Mitochondrial Membrane Potential (MMP) Assessment (JC-1 Staining): To investigate ERPP's impact on mitochondrial function, a critical step in apoptosis, by measuring changes in membrane potential.
  • Gene Expression Analysis (RT-qPCR): To examine the expression levels of key apoptosis-related genes (Bax, Bcl-2, CYCS, CASP-3) and angiogenesis-related genes (Vegfaa) to elucidate the underlying molecular mechanisms.
  • Antioxidant Activity Assays (Hydroxyl Radical, ABTS+, DPPH• Scavenging): To evaluate ERPP's capacity to neutralize free radicals, a crucial aspect of its potential anti-cancer effects.
  • Intracellular ROS Detection: To measure the effect of ERPP on reactive oxygen species levels within cancer cells.
  • In Vivo Assays:
    • Zebrafish HT-29 Xenograft Model: This model was used to assess ERPP's anti-tumor efficacy in a living organism.
  • Tumor Growth Quantification: Microscopy and fluorescence imaging were used to measure tumor volume and assess the inhibition of tumor growth.
  • Tumor Angiogenesis Assessment: The formation of new blood vessels supplying the tumor was visualized and quantified using fluorescent imaging in transgenic zebrafish.
  • Tumor Metastasis Assessment: The migration of tumor cells within the zebrafish model was evaluated using fluorescence imaging.
  • Apoptosis Assessment in Zebrafish: Acridine orange staining was used to visualize and quantify apoptotic cells within the tumors in the zebrafish model.

Datasets

Not discussed in the paper.

Key Insights and Ideas

  • ERPP as a Potent Anti-CRC Agent: The study strongly suggests that ERPP is a promising natural compound with significant anti-cancer activity against colorectal cancer.
  • Mitochondrial Apoptosis is Key: A central finding is that ERPP primarily induces cancer cell death by triggering the mitochondrial apoptosis pathway. This involves altering the balance of pro- and anti-apoptotic proteins (Bax/Bcl-2), leading to mitochondrial membrane depolarization, cytochrome c release, and caspase activation.
  • Dual Action: Anti-angiogenesis and Antioxidant Properties: Beyond directly killing cancer cells, ERPP also exhibits anti-angiogenic effects, hindering tumor blood vessel formation, and potent antioxidant capabilities, which can further suppress tumor growth and protect against oxidative stress-induced damage.
  • Zebrafish as a Valid In Vivo Model: The study successfully utilizes the zebrafish xenograft model to validate the in vitro findings, demonstrating ERPP's efficacy in a living system and highlighting the model's utility for preclinical cancer research.
  • Synergistic Effects: The combination of apoptosis induction, anti-angiogenesis, and antioxidant activity likely contributes to ERPP's overall anti-tumor efficacy, offering a multi-faceted approach to cancer management.

Key Results

  • In Vitro:
    • ERPP significantly inhibited HT-29 cell proliferation, colony formation, and migration in a dose-dependent manner.
  • ERPP induced apoptosis in HT-29 cells, with a dose-dependent increase in the apoptotic rate.
  • ERPP treatment led to a significant decrease in mitochondrial membrane potential (MMP), indicated by a reduction in the red/green fluorescence ratio from 10.87 to 0.35.
  • RT-qPCR analysis showed ERPP upregulated pro-apoptotic genes (Bax) and downregulated anti-apoptotic genes (Bcl-2), leading to increased cytochrome c and caspase-3 expression.
  • ERPP demonstrated potent antioxidant activity, achieving an 80.2% hydroxyl radical scavenging rate at 4 mg/mL and significantly attenuating intracellular ROS levels in HT-29 cells.
  • In Vivo (Zebrafish Model):
    • ERPP significantly reduced tumor growth in HT-29 xenografts, with high-dose ERPP showing efficacy comparable to 5-FU.
  • ERPP treatment significantly attenuated tumor angiogenesis by reducing subvascular sprouts.
  • ERPP effectively inhibited tumor cell migration and metastasis in the zebrafish model.
  • ERPP promoted apoptosis in tumor cells within the zebrafish xenografts.
  • ERPP downregulated the expression of the Vegfaa gene, further supporting its anti-angiogenic effects.

Limitations and Future Work

  • Mechanism of Cellular Entry: The authors acknowledge that further studies are needed to explore how ERPP enters the cell, which could provide deeper insights into its intracellular mechanisms.
  • In Vivo Efficacy Comparison: While ERPP showed comparable efficacy to 5-FU in some aspects, direct head-to-head comparisons with established chemotherapeutics across various cancer models could further solidify its therapeutic potential.
  • Long-term Toxicity and Efficacy: While the study demonstrates promising acute effects, long-term toxicity studies and efficacy evaluations in more complex animal models would be crucial for its translation to clinical applications.
  • Combination Therapies: Investigating the synergistic effects of ERPP in combination with existing cancer therapies could unlock new treatment strategies.
  • Human Clinical Trials: The ultimate validation of ERPP's therapeutic potential would require rigorous human clinical trials.

Summary updated

Abstract

Colorectal cancer (CRC) remains a predominant cause of global cancer-related mortality, highlighting the pressing demand for innovative therapeutic strategies. Natural polysaccharides have emerged as promising candidates in cancer research due to their multifaceted anticancer mechanisms and tumor-suppressive potential across diverse malignancies. In this study, we enzymatically extracted a polysaccharide, named ERPP, from <i>Ruditapes philippinarum</i> and comprehensively evaluated its anti-colorectal cancer activity. We conducted in vitro assays, including CCK-8 proliferation, clonogenic survival, scratch wound healing, and Annexin V-FITC/PI apoptosis staining, and the results demonstrated that ERPP significantly inhibited HT-29 cell proliferation, suppressed colony formation, impaired migratory capacity, and induced apoptosis. JC-1 fluorescence assays provided further evidence of mitochondrial membrane potential (MMP) depolarization, as manifested by a substantial reduction in the red/green fluorescence ratio (from 10.87 to 0.35). These antitumor effects were further validated in vivo using a zebrafish HT-29 xenograft model. Furthermore, ERPP treatment significantly attenuated tumor angiogenesis and downregulated the expression of the vascular endothelial growth factor A (<i>Vegfaa</i>) gene in the zebrafish xenograft model. Mechanistic investigations revealed that ERPP primarily activated the mitochondrial apoptosis pathway. RT-qPCR analysis showed an upregulation of the pro-apoptotic gene <i>Bax</i> and a downregulation of the anti-apoptotic gene <i>Bcl-2</i>, leading to cytochrome c (<i>CYCS</i>) release and caspase-3 (<i>CASP-3</i>) activation. Additionally, ERPP exhibited potent antioxidant capacity, achieving an 80.2% hydroxyl radical scavenging rate at 4 mg/mL. ERPP also decreased reactive oxygen species (ROS) levels within the tumor cells, thereby augmenting anticancer efficacy through its antioxidant activity. Collectively, these findings provide mechanistic insights into the properties of ERPP, underscoring its potential as a functional food component or adjuvant therapy for colorectal cancer management.
BibTeX
@inproceedings{liu2025antitumor,
  author = {Mengyue Liu and Weixia Wang and Haoran Wang and Shuang Zhao and Dongli Yin and Haijun Zhang and Changqing Zou and Shengcan Zou and Jia Yu and Yuxi Wei},
  title = {{Antitumor Activity of Ruditapes philippinarum Polysaccharides Through Mitochondrial Apoptosis in Cellular and Zebrafish Models}},
  booktitle = {Marine},
  year = {2025},
  doi = {10.3390/md23080304},
}
Figure